NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Systems Biology Approach to Malaria Immunity

Phase 1

Completed

Conditions: Plasmodium Falciparum Infection

Interventions: Biological: NF54 P. falciparum malaria challenge

First Posted Date: 2017-01-09

Last Posted Date: 2021-06-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT03014258

Locations: 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States

VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

Phase 1

Completed

Conditions: HIV Prevention

Interventions: Biological: VRC-HIVMAB075-00-AB

First Posted Date: 2017-01-09

Last Posted Date: 2020-10-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 26

Registration Number: NCT03015181

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

Phase 1

Completed

Conditions: Avian Influenza

Interventions: Drug: MF59
Drug: AS03
Biological: Monovalent Influenza A/H5N8 vaccine

First Posted Date: 2017-01-09

Last Posted Date: 2024-07-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 388

Registration Number: NCT03014310

Locations: 🇺🇸
Duke Vaccine and Trials Unit, Durham, North Carolina, United States
🇺🇸
The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD), Galveston, Texas, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States

and more 4 locations

Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

Phase 1

Completed

Conditions: Zika Virus Infection

Interventions: Other: Placebo
Biological: Zika Virus Purified Inactivated Vaccine (ZPIV)

First Posted Date: 2017-01-02

Last Posted Date: 2023-04-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 91

Registration Number: NCT03008122

Locations: 🇵🇷
Ponce School of Medicine CAIMED Center, Ponce, Puerto Rico

Safety and Immune Response to a Clade C DNA HIV Vaccine

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: DNA-HIV-PT123 vaccine
Biological: Placebo
Biological: Protein/MF59 vaccine

First Posted Date: 2016-12-20

Last Posted Date: 2019-06-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 132

Registration Number: NCT02997969

Locations: 🇿🇦
Aurum Tembisa CRS, Johannesburg, Gauteng, South Africa
🇿🇦
Isipingo CRS, Westville, Kwa Zulu Natal, South Africa
🇿🇦
Aurum Institute Klerksdorp CRS, Klerksdorp, North West Province, South Africa

and more 2 locations

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

Phase 2

Terminated

Conditions: Autosomal-dominant Hyper-IgE Syndrome

Interventions: Drug: NDV-3A

First Posted Date: 2016-12-19

Last Posted Date: 2020-06-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3

Registration Number: NCT02996448

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

Phase 1

Completed

Conditions: Zika-Specific Immune Response
Prevention of Zika Infection

Interventions: Biological: VRC-ZKADNA090-00-VP

First Posted Date: 2016-12-19

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT02996461

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults

Phase 1

Completed

Conditions: Plasmodium Falciparum Infection

Interventions: Drug: Artesunate
Drug: Chloroquine
Biological: PfSPZ (NF54) Challenge
Other: Placebo

First Posted Date: 2016-12-19

Last Posted Date: 2019-12-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 62

Registration Number: NCT02996695

Locations: 🇲🇱
University of Bamako - Epidemiology of Parasitic Diseases - Malaria Research and Training Center, Sikasso, Mali

Impact of Malaria on Pregnant Women in Ouelessebougou, Mali

Completed

Conditions: Malaria

First Posted Date: 2016-11-28

Last Posted Date: 2023-03-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7691

Registration Number: NCT02974608

Locations: 🇲🇱
Ouelessebougou Clinical Research Center (Malaria Research and Training Center), Bamako, Mali

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

Recruiting

Conditions: SAVI
CANDLE
DIRA
NLRC4-MAS
NOMID

First Posted Date: 2016-11-28

Last Posted Date: 2025-01-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3200

Registration Number: NCT02974595

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy